Opioid antagonists are a type of drug which blunts the effects of narcotics such as heroin and morphine, and might help reduce nicotine addiction by blocking some of the rewarding effects of smoking. Our review identified eight trials of naltrexone, a long-acting opioid antagonist. The trials included over 1200 smokers. Half the trials gave everyone nicotine replacement therapy and tested whether naltrexone had any additional benefit. Compared to a placebo, naltrexone did not increase the proportion of people who had stopped smoking, at the end of treatment, or at six months or more after treatment, either on its own or added to NRT. The available evidence does not suggest that opioid antagonists such as naltrexone assist smoking cessation.
Do opioid antagonists such as naltrexone help people to stop smoking?
6 June 2013
This record should be cited as:
David SP, Lancaster T, Stead LF, Evins A, Prochaska JJ. Opioid antagonists for smoking cessation. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD003086. DOI: 10.1002/14651858.CD003086.pub3
Assessed as up to date:
18 April 2013
More like this
- Can interventions delivered by mobile phones help people to stop smoking?
- Can nicotine receptor partial agonists, including cytisine, dianicline and varenicline, help people to stop smoking?
- Can Internet-based interventions help people to stop smoking?
- Does mecamylamine help people to stop smoking
- Does support and intervention from nurses help people to stop smoking?